|
1
|
Chen YB, Rahemtullah A and Hochberg E:
Primary effusion lymphoma. Oncologist. 12:569–576. 2007.
|
|
2
|
Nador RG, Cesarman E, Chadburn A, Dawson
DB, Ansari MQ, Sald J and Knowles DM: Primary effusion lymphoma: a
distinct clinicopathologic entity associated with the Kaposi’s
sarcoma-associated herpes virus. Blood. 88:645–656. 1996.
|
|
3
|
Boulanger E, Gerard L, Gabarre J, Molina
JM, Rapp C, Abino JF, Cadranel J, Chevret S and Oksenhendler E:
Prognostic factors and outcome of human herpesvirus 8-associated
primary effusion lymphoma in patients with AIDS. J Clin Oncol.
23:4372–4380. 2005.
|
|
4
|
An J, Sun Y, Sun R and Rettig MB: Kaposi’s
sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6
expression: the role of the NF-kappaB and JNK/AP1 pathways.
Oncogene. 22:3371–3385. 2003.
|
|
5
|
Guasparri I, Keller SA and Cesarman E:
KSHV vFLIP is essential for the survival of infected lymphoma
cells. J Exp Med. 199:993–1003. 2004.
|
|
6
|
Field N, Low W, Daniels M, Howell S,
Daviet L, Boshoff C and Collins M: KSHV vFLIP binds to IKK-gamma to
activate IKK. J Cell Sci. 116:3721–3728. 2003.
|
|
7
|
Liu L, Eby MT, Rathore N, Sinha SK, Kumar
A and Chaudhary PM: The human herpes virus 8-encoded viral FLICE
inhibitory protein physically associates with and persistently
activates the Ikappa B kinase complex. J Biol Chem.
277:13745–13751. 2002.
|
|
8
|
Keller SA, Hernandez-Hopkins D, Vider J,
Ponomarev V, Hyjek E, Schattner EJ and Cesarman E: NF-kappaB is
essential for the progression of KSHV- and EBV-infected lymphomas
in vivo. Blood. 107:3295–3302. 2006.
|
|
9
|
Keller SA, Schattner EJ and Cesarman E:
Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary
effusion lymphoma cells. Blood. 96:2537–2542. 2000.
|
|
10
|
Suh JJ, Pettinati HM, Kampman KM and
O’Brien CP: The status of disulfiram: a half of a century later. J
Clin Psychopharmacol. 26:290–302. 2006.
|
|
11
|
Sunderman FW Sr: The extended therapeutic
role of dithiocarb (sodium diethyldithiocarbamate) from nickel
poisoning to AIDS. Ann Clin Lab Sci. 22:245–248. 1992.
|
|
12
|
Pang H, Chen D, Cui QC and Dou QP: Sodium
diethyldithiocarbamate, an AIDS progression inhibitor and a
copper-binding compound, has proteasome-inhibitory and
apoptosis-inducing activities in cancer cells. Int J Mol Med.
19:809–816. 2007.
|
|
13
|
Brewer C: Long-term, high-dose disulfiram
in the treatment of alcohol abuse. Br J Psychiatry. 163:687–689.
1993.
|
|
14
|
Hersh EM, Brewton G, Abrams D, Bartlett J,
Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas JJ, Landesman S, et
al: Ditiocarb sodium (diethyldithiocarbamate) therapy in patients
with symptomatic HIV infection and AIDS. A randomized,
double-blind, placebo-controlled, multicenter study. JAMA.
265:1538–1544. 1991.
|
|
15
|
Reisinger EC, Kern P, Ernst M, Bock P,
Flad HD and Dietrich M: Inhibition of HIV progression by
dithiocarb. German DTC Study Group. Lancet. 335:679–682. 1990.
|
|
16
|
Shinobu LA, Jones SG and Jones MM:
Mobilization of aged cadmium deposits by dithiocarbamates. Arch
Toxicol. 54:235–242. 1983.
|
|
17
|
Cvek B and Dvorak Z: Targeting of nuclear
factor-kappaB and proteasome by dithiocarbamate complexes with
metals. Curr Pharm Des. 13:3155–3167. 2007.
|
|
18
|
Renne R, Zhong W, Herndier B, McGrath M,
Abbey N, Kedes D and Ganem D: Lytic growth of Kaposi’s
sarcoma-associated herpesvirus (human herpesvirus 8) in culture.
Nat Med. 2:342–346. 1996.
|
|
19
|
Ono A, Hattori S, Kariya R, Iwanaga S,
Taura M, Harada H, Suzu S and Okada S: Comparative study of human
hematopoietic cell engraftment into BALB/c and C57BL/6 strain of
rag-2/jak3 double-deficient mice. J Biomed Biotechnol.
2011.539748:
|
|
20
|
Hersh EM, Funk CY, Petersen EA, Ryschon KL
and Mosier DE: Dose response and timing effects in the therapy of
the LP-BM5 murine retrovirus-induced lymphoproliferative
immunodeficiency disease with diethyldithiocarbamate. Int J
Immunopharmacol. 15:137–143. 1993.
|
|
21
|
Aoki Y, Jaffe ES, Chang Y, Jones K,
Teruya-Feldstein J, Moore PS and Tosato G: Angiogenesis and
hematopoiesis induced by Kaposi’s sarcoma-associated
herpesvirus-encoded interleukin-6. Blood. 93:4034–4043. 1999.
|
|
22
|
Kanno S, Matsukawa E, Miura A, Shouji A,
Asou K and Ishikawa M: Diethyldithiocarbamate-induced cytotoxicity
and apoptosis in leukemia cell lines. Biol Pharm Bull. 26:964–968.
2003.
|
|
23
|
Asou H, Said JW, Yang R, Munker R, Park
DJ, Kamada N and Koeffler HP: Mechanisms of growth control of
Kaposi’s sarcoma-associated herpes virus-associated primary
effusion lymphoma cells. Blood. 91:2475–2481. 1998.
|
|
24
|
Takahashi-Makise N, Suzu S, Hiyoshi M,
Ohsugi T, Katano H, Umezawa K and Okada S: Biscoclaurine alkaloid
cepharanthine inhibits the growth of primary effusion lymphoma in
vitro and in vivo and induces apoptosis via suppression of the
NF-kappaB pathway. Int J Cancer. 125:1464–1472. 2009.
|
|
25
|
Zhang C, Hazarika P, Ni X, Weidner DA and
Duvic M: Induction of apoptosis by bexarotene in cutaneous T-cell
lymphoma cells: relevance to mechanism of therapeutic action. Clin
Cancer Res. 8:1234–1240. 2002.
|
|
26
|
Porter AG and Janicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
|
|
27
|
Sauna ZE, Shukla S and Ambudkar SV:
Disulfiram, an old drug with new potential therapeutic uses for
human cancers and fungal infections. Mol Biosyst. 1:127–134.
2005.
|
|
28
|
Cataldi A, Rapino M, Centurione L,
Sabatini N, Grifone G, Garaci F and Rana R: NF-kappaB activation
plays an antiapoptotic role in human leukemic K562 cells exposed to
ionizing radiation. J Cell Biochem. 89:956–963. 2003.
|
|
29
|
Herrero JA, Mathew P and Paya CV: LMP-1
activates NF-kappa B by targeting the inhibitory molecule I kappa B
alpha. J Virol. 69:2168–2174. 1995.
|
|
30
|
Spiller SE, Logsdon NJ, Deckard LA and
Sontheimer H: Inhibition of nuclear factor kappa-B signaling
reduces growth in medulloblastoma in vivo. BMC Cancer.
11:1362011.
|
|
31
|
Safa M, Zand H, Mousavizadeh K, Kazemi A,
Bakhshayesh M and Hayat P: Elevation of cyclic AMP causes an
imbalance between NF-kappaB and p53 in NALM-6 cells treated by
doxorubicin. FEBS Lett. 584:3492–3498. 2010.
|
|
32
|
Han SS, Kim K, Hahm ER, Park CH, Kimler
BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH
and Park S: Arsenic trioxide represses constitutive activation of
NF-kappaB and COX-2 expression in human acute myeloid leukemia,
HL-60. J Cell Biochem. 94:695–707. 2005.
|
|
33
|
Cvek B and Dvorak Z: The value of
proteasome inhibition in cancer. Can the old drug, disulfiram, have
a bright new future as a novel proteasome inhibitor? Drug Discov
Today. 13:716–722. 2008.
|
|
34
|
Kona FR, Buac D and Burger AM: Disulfiram,
and disulfiram derivatives as novel potential anticancer drugs
targeting the ubiquitin proteasome system in both preclinical and
clinical studies. Curr Cancer Drug Targets. 11:338–346. 2011.
|
|
35
|
Kaplan CS, Petersen EA, Yocum D and Hersh
EM: A randomized, controlled dose response study of intravenous
sodium diethyldithiocarbamate in patients with advanced human
immunodeficiency virus infection. Life Sci. 45:iii–ix. 1989.
|
|
36
|
Komanduri KV, Luce JA, McGrath MS,
Herndier BG and Ng VL: The natural history and molecular
heterogeneity of HIV-associated primary malignant lymphomatous
effusions. J Acquir Immune Defic Syndr Hum Retrovirol. 13:215–226.
1996.
|
